Dermatology and Therapy最新文献

{"title":"Integrative Proteomics and Genomics Identify Novel Biomarkers and Therapeutic Targets in Vitiligo via Mendelian Randomization.","authors":"Chenjue Yan, Ling Jiang, Yibo Hu, Ting You, Jing Chen, Songjiang Wu","doi":"10.1007/s13555-025-01448-5","DOIUrl":"10.1007/s13555-025-01448-5","url":null,"abstract":"<p><strong>Introduction: </strong>Given that the proteome is a major source of therapeutic targets, we conducted a proteome-wide Mendelian randomization (MR) combined with transcriptome sequencing analysis to identify candidate protein markers and therapeutic targets for vitiligo.</p><p><strong>Methods: </strong>Based on protein quantitative trait loci (pQTLs) and genetic associations with vitiligo obtained from the European Bioinformatics Institute (EBI) database (60 vitiligo cases and 402,672 controls), and the UK Biobank (95 vitiligo cases and 337,064 controls), bidirectional MR and colocalization analyses identified genetically predicted levels of nine proteins collectively linked to vitiligo risk. Based on the RNA-seq data and single-cell RNA-seq data of vitiligo, bioinformatics analysis and model prediction of genes associated with vitiligo progression evaluated the relationship between candidate core proteins and the development of vitiligo.</p><p><strong>Results: </strong>Four proteins (KLF4, MYL4, TNFRSF13C, TNFSF13B) were associated with lower vitiligo risk, while five proteins (ALPI, CDH1, ITGB1, SERPINH1, TNFSF10) were linked to higher risk. Of these, three proteins (KLF4, TNFRSF13C, and TNFSF10) were high priority with the most convincing evidence. Bioinformatics analysis and model prediction of genes associated with vitiligo progression showed these three protein-coding genes were significantly associated with vitiligo occurrence, and their functions were related to cell cycle, apoptosis, oxidative stress, inflammatory response, and immune infiltration. Mechanistically, the expression of these key candidate molecules was regulated by various miRNAs and transcription factors. The druggability assessment and molecular docking identified some drugs targeting these proteins, such as APTO-2535 and butyric acid.</p><p><strong>Conclusion: </strong>KLF4, TNFRSF13C, and TNFSF10 may be involved in regulating the occurrence and development of vitiligo, providing potential targets for improving the diagnosis and treatment of vitiligo.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2159-2177"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comprehensive Narrative Review of the Challenges Surrounding Cutaneous SCC.","authors":"Sarah C Beach, Austin S Cusick, Aaron S Farberg, Shannon C Trotter","doi":"10.1007/s13555-025-01470-7","DOIUrl":"10.1007/s13555-025-01470-7","url":null,"abstract":"<p><p>Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer (NMSC) and is predominantly found in the head and neck region. With an annual increase in NMSC diagnoses, cSCC presents significant diagnostic and therapeutic challenges. This review discusses the many risk factors for the development of cSCC, outlines the criteria for defining high-risk cSCC, and examines treatment approaches of these tumors based on risk stratification. While most cSCCs are treatable with surgical excision, approximately 5% metastasize, with head and neck cSCC showing poor prognosis once metastasis occurs. High-risk cSCCs, which are more likely to recur or metastasize, are often characterized by larger size, deeper invasion, and histopathological features such as perineural or vascular involvement. However, there is not a standardized definition of high-risk cSCC, leading to variability in prognosis and treatment approaches. While widely adopted staging systems such as the American Joint Committee on Cancer 8th Edition (AJCC8) and the Brigham and Women's Hospital (BWH) classification provide a useful framework based primarily on tumor size and extent, they have limitations-particularly in accounting for patient-specific factors. Given the complexity of factors involved in clinical decision-making, treatment recommendations warrant a case-by-case application of criteria on an individualized level, incorporating variables beyond conventional staging paradigms. While surgical excision is indicated for high-risk invasive cSCC, other treatments may include adjuvant radiation therapy (ART) and systemic therapies such as immune checkpoint inhibitors (cemiplimab, pembrolizumab, and cosibelimab) and epidermal growth factor receptor (EGFR) inhibitors (cetuximab). Gene expression profiling (GEP) is a tool that offers prognostic information to help assess metastatic risk and guide treatment decisions; however, prospective, nonbiased studies are needed to validate its utility to support broader integration into clinical practice. Despite advancements, inconsistent application of ART and biopsy limitations persist, highlighting the need for a standardized, evidence-based approach to cSCC management. This review highlights the challenges surrounding cSCC and the potential value of molecular tools to improve outcomes for patients with high-risk cSCC.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2015-2029"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness and Safety of Risankizumab in Psoriasis: A Comprehensive Analysis from the Saudi Arabia Psoriasis Registry (PSORSA).","authors":"Mohammed Ibrahim Fatani, Abdulaziz Madani, Fahad Alzuriqan, Abdullah Albadri, Ahmed Aljedai, Hajer Almudaiheem, Maysa Tariq Eshmawi","doi":"10.1007/s13555-025-01493-0","DOIUrl":"https://doi.org/10.1007/s13555-025-01493-0","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic immune-mediated skin condition that has a substantial impact on patients' quality of life. The Saudi Arabia Psoriasis Registry (PSORSA) was established to address long-term real-world data (RWD) on systemic and biologic therapies in the region. This observational cohort study provides a comprehensive analysis of baseline disease characteristics, comorbidities, and treatment efficacy among patients enrolled in PSORSA, with an emphasis on risankizumab.</p><p><strong>Methods: </strong>Data were sourced from a governmental online database covering multiple healthcare centers. Patients eligible for biologics were followed at baseline and at weeks 16, 28, 40, and 52 to evaluate disease severity, quality of life, and adherence. Statistical analyses were conducted using Jamovi and R. Descriptive statistics were performed for categorical and continuous variables. p-Values < 0.05 were considered significant.</p><p><strong>Results: </strong>The study cohort included 313 patients. Plaque psoriasis was the most prevalent clinical type (93.9%). An analysis of treatment history revealed that 39.6% of patients had prior therapy exposure, and all patients received risankizumab as a biologic therapy. At baseline, the mean Psoriasis Area and Severity Index (PASI) score was 25.49. By week 52, it had decreased to 0.358, indicating complete clearance. PASI scores showed a steady and substantial reduction over time, with an 88% reduction at week 16, 96% at week 28, 97.5% at week 40, and 98.5% by week 52, demonstrating a strong and sustained treatment effect (p < 0.001). Additionally, risankizumab exhibited a favorable drug survival profile, with many patients maintaining treatment beyond 122 weeks.</p><p><strong>Conclusion: </strong>This study represents the first real-world assessment of risankizumab for moderate-to-severe psoriasis in Saudi Arabia. The findings demonstrate that risankizumab is an effective and well-tolerated treatment for moderate-to-severe psoriasis in this Saudi Arabian cohort. However, future studies should explore long-term safety outcomes and the comparative effectiveness of risankizumab and emerging biologics in diverse patient populations.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis).","authors":"Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, Antonio Costanzo, Matteo Bianco, Piergiorgio Malagoli, Francesco Messina, Francesca Gaiani, Silvia Mariel Ferrucci, Angelo Valerio Marzano, Francesca Barei, Simone Ribero, Michela Ortoncelli, Francesco Leo, Maddalena Napolitano, Andrea Cosenza, Cataldo Patruno, Mario Bruno Guanti, Anna Balato, Francesco Loconsole, Claudio Sciarrone, Federica Veronese, Elena Pezzolo, Anna Graziella Burroni, Massimo Gola, Carlotta Gurioli, Flavia Manzo Margiotta, Maria Letizia Musumeci, Francesca Satolli, Giuseppe Amoruso, Maria Esposito, Caterina Foti, Paolo Pella, Anna Campanati, Andrea Carugno, Nicola Zerbinati, Martina Maurelli, Ilaria Trave, PierGiacomo Calzavara-Pinton, Luca Bettolini","doi":"10.1007/s13555-025-01477-0","DOIUrl":"https://doi.org/10.1007/s13555-025-01477-0","url":null,"abstract":"<p><strong>Introduction: </strong>Janus kinase (JAK) inhibitors are effective systemic treatments for moderate-to-severe atopic dermatitis (AD), rapidly controlling symptoms and improving quality of life. However, the impact of body mass index (BMI) on therapeutic response remains unclear.</p><p><strong>Methods: </strong>This multicenter retrospective study analyzed data from 388 adult AD patients treated with upadacitinib, abrocitinib, or baricitinib across 25 Italian dermatology centers between May 2022 and July 2024. Patients were classified as overweight (BMI ≥ 25) or non-overweight (BMI < 25), with disease severity assessed using EASI, IGA, and Numerical Rating Scales (NRS) for pruritus and sleep disturbance over 104 weeks. The effect of different treatment dosages was also evaluated.</p><p><strong>Results: </strong>No significant BMI-related differences in clinical outcomes were noted at most timepoints. However, in the upadacitinib 15 mg group, non-overweight patients showed greater EASI and pruritus improvements at Week 4 (p = 0.037, p = 0.039), although these differences resolved subsequently. At Week 104, higher BMI modestly reduced EASI improvement (p = 0.045) in multivariable analysis.</p><p><strong>Conclusions: </strong>Treatment dosage consistently influenced clinical improvement regardless of BMI. These findings confirm the efficacy of JAK inhibitors across BMI categories, suggesting minimal short-term BMI influence but highlighting potential long-term considerations in overweight patients, emphasizing personalized dosing strategies and prolonged monitoring.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial.","authors":"Lin Cai, Chengxin Li, Shanshan Li, Xiaodong Zhang, Gang Wang, Jianbin Yu, Kun Huang, Hong Fang, Yangfeng Ding, Jinyan Wang, Congjun Jiang, Qianjin Lu, Juan Tao, Jianzhong Zhang","doi":"10.1007/s13555-025-01480-5","DOIUrl":"10.1007/s13555-025-01480-5","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).","authors":"Andreas Pinter, Alan Brnabic, Emanuele Trovato, Lluís Puig, Jose-Manuel Carrascosa, Thierry Boyé, Matteo Megna, Silvia Sabatino, Inmaculada De La Torre, Julia-Tatjana Maul","doi":"10.1007/s13555-025-01494-z","DOIUrl":"https://doi.org/10.1007/s13555-025-01494-z","url":null,"abstract":"<p><strong>Introduction: </strong>The Psoriasis Study of Health Outcomes (PSoHO) is an international, prospective, non-interventional study investigating the comparative effectiveness and durability of biologic treatments for patients with moderate-to-severe psoriasis (PsO) over 36 months. Patients were grouped into cohorts based on biologic class: anti-interleukin (IL)-17A/receptor A (anti-IL-17A), anti-IL-12/23, anti-IL-23 and anti-tumor necrosis factor (TNF)-α for the purpose of comparison. Additionally, the durability and effectiveness of individual biologic treatments were compared to ixekizumab (IXE).</p><p><strong>Methods: </strong>Effectiveness was assessed using Psoriasis Area and Severity Index (PASI) 90 and PASI100 response rates and durability, defined as achieving therapeutic response (PASI90/100) at week 12 and its maintenance at months 6, 12, 18 and 24. Statistical analysis included unadjusted descriptive summaries and model-based comparisons that accounted for baseline confounders using the frequentist model averaging (FMA) framework and marginal structural models (MSM) that accounted for both baseline and time-varying confounders.</p><p><strong>Results: </strong>Results demonstrated that patients treated with anti-IL-17A biologics had significantly higher odds of achieving PASI100 and PASI90 compared to those treated with anti-IL-12/23 and anti-TNFα biologics. Specifically, at 24 months, IXE showed greater PASI100 and PASI90 response rates compared to adalimumab (ADA) and ustekinumab (UST), with adjusted odds ratios of 1.9 and 2.3 for PASI100 and 2.0 and 2.5 for PASI90, respectively. IXE-treated patients also exhibited higher durability rates for PASI100 and PASI90 compared to ADA, UST, secukinumab (SEC), tildrakizumab (TILD) and guselkumab (GUS), with adjusted odds ratios (non-responder imputation [NRI]) between 1.7 and 4.3 (PASI100) and 1.6 and 4.2 (PASI90), while being similar to risankizumab (RIS).</p><p><strong>Conclusion: </strong>This study provides valuable real-world data on the long-term effectiveness and durability of biologic treatments for PsO, emphasizing the advantages of anti-IL-17A biologics, particularly IXE, in achieving and maintaining therapeutic responses. These findings support dermatologists in making informed decisions regarding PsO treatment strategies.</p><p><strong>Trial number: </strong>The study was registered at the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCEPP24207).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustainability in Cosmetic Dermatology: Moving Toward an Ecologically Responsible Future.","authors":"Diala Haykal, Frédéric Flament, Christopher Rowland Payne, Sergio Schalka, Michel Philippe, Olivier Rolland, Pascale Mora, Hugues Cartier, Brigitte Dréno","doi":"10.1007/s13555-025-01488-x","DOIUrl":"https://doi.org/10.1007/s13555-025-01488-x","url":null,"abstract":"<p><p>Sustainability in cosmetic dermatology is becoming a pivotal aspect of modern clinical practice, aligning with global environmental and public health objectives. This commentary explores the ecological impact of dermatological procedures and products, emphasizing the necessity of integrating sustainable practices to mitigate environmental harm. Key focus areas include reducing carbon footprint through energy-efficient clinics, ethical sourcing of ingredients, eco-friendly packaging, and the adoption of circular economy principles to minimize waste. Additionally, technological advancements, such as artificial intelligence (AI) and blockchain, are transforming sustainability in dermatology by optimizing resource allocation, enhancing transparency, and reducing clinical waste. Regulatory policies and industry standards are also evolving to support environmentally responsible practices. Embedding sustainability into dermatology practice contributes not only to environmental goals but also to the long-term resilience and adaptability of clinics in a shifting regulatory and consumer landscape. By fostering innovation, ethical responsibility, and regulatory compliance, sustainability initiatives in cosmetic dermatology contribute to a more resilient, health-oriented future for both patients and the planet.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.","authors":"Andrew F Alexis, Leon Kircik, Raj Chovatiya, Zakiya P Rice, Weily Soong, Tina Bhutani, Philip M Brown, Stephen C Piscitelli, David S Rubenstein, Anna M Tallman, April W Armstrong","doi":"10.1007/s13555-025-01489-w","DOIUrl":"https://doi.org/10.1007/s13555-025-01489-w","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with atopic dermatitis (AD) and skin of color have heterogeneous presentations and treatment outcomes, however, they are underrepresented in trials. In the ADORING 1 and 2 phase 3, 8-week randomized trials, tapinarof cream 1% once daily (QD) demonstrated superior efficacy versus vehicle in adults and children down to age 2 years with AD. These analyses evaluate efficacy of tapinarof cream 1% QD stratified by race and Fitzpatrick skin type.</p><p><strong>Methods: </strong>The primary endpoint was a Validated Investigator Global Assessment for Atopic Dermatitis™ (vIGA-AD™) score of 0 (clear) or 1 (almost clear) and ≥ 2-grade improvement from baseline at week 8. Secondary endpoints included achieving ≥ 75% improvement in Eczema Area and Severity Index (EASI75). Efficacy evaluations used race categories of Asian, Black or African American, and white, and Fitzpatrick skin types I-III and IV-VI.</p><p><strong>Results: </strong>In ADORING 1 and 2, 407 and 406 patients were randomized to tapinarof or vehicle QD (7.3-17.0% Asian; 25.9-35.1% Black/African American 43.0-57.7% white), respectively. Across trials, > 50% had Fitzpatrick skin types IV-VI. Tapinarof demonstrated significant efficacy in adults and children. By race in both trials, the primary endpoint was met by consistently higher proportions treated with tapinarof than vehicle: Asian, 39.5-48.9% versus 3.7-18.5%; Black/African American, 43.1-47.0% versus 17.5-24.1%; white, 49.4-52.1% versus 12.2-14.5%, respectively. Similar, superior responses were reported across Fitzpatrick skin type groups with tapinarof versus vehicle: I-III, 44.8-49.9% versus 13.5-17.7%; IV-VI, 46.8-49.6% versus 15.3-19.5%. EASI75 responses were similarly higher and consistent with tapinarof versus vehicle. Adverse events were mostly mild or moderate, leading to low trial discontinuations (lower with tapinarof than vehicle).</p><p><strong>Conclusions: </strong>Tapinarof demonstrated consistent efficacy and was well tolerated versus vehicle in a large, diverse population with AD, regardless of race or Fitzpatrick skin type.</p><p><strong>Trial registration: </strong>Clinicaltrials.gov, NCT05014568, NCT05032859. Graphical Abstract avaliable for this article.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Complete/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry.","authors":"Neal Bhatia, Charles W Lynde, Luz Fonacier, Liyang Shao, Kwinten Bosman, Andrew Korotzer","doi":"10.1007/s13555-025-01478-z","DOIUrl":"https://doi.org/10.1007/s13555-025-01478-z","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduction in Facial Sebum Production Following Treatment with Clascoterone Cream 1% in Patients with Acne Vulgaris: 12-Week Interim Analysis.","authors":"Zoe D Draelos, Kizito Kyeremateng, Nicholas Squittieri","doi":"10.1007/s13555-025-01495-y","DOIUrl":"https://doi.org/10.1007/s13555-025-01495-y","url":null,"abstract":"<p><strong>Introduction: </strong>In vitro, clascoterone inhibits androgen-induced sebum production-a key driver of acne pathogenesis-although the exact mechanism of action of clascoterone for the treatment of acne is unknown. This study evaluated reductions in casual sebum production following 12 weeks of clascoterone cream 1% treatment in patients with acne.</p><p><strong>Methods: </strong>Patients ≥ 12 years old with mild-to-moderate acne applied clascoterone cream 1% twice daily for 12 weeks. The primary endpoint was the reduction in casual sebum measurements at Week 12. Additional endpoints included Investigator's Global Assessment (IGA) score, inflammatory and noninflammatory lesion counts (ILC and NILC), and tolerability. Data were analyzed using Student's t-test and Wilcoxon signed-rank test.</p><p><strong>Results: </strong>Forty patients with a mean age of 20.9 years were enrolled, all of whom completed Week 12. Significant percentage reductions from baseline were observed in sebum measurements (27%), ILC (54%), and NILC (34%; all p < 0.001), and patients achieved a 29% reduction in IGA score. No tolerability or safety issues were identified during the 12-week interim analysis period.</p><p><strong>Conclusion: </strong>Clascoterone cream 1% led to significant reductions in sebum measurements with improvements in acne severity and was well tolerated.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier, NCT06415279.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}